Menlo Therapeutics Files for Up-to-$97.75M IPO

Menlo Therapeutics, a drug developer focused on developing its single pipeline candidate for dermatological indications and refractory chronic cough, will seek to raise up to $97.75 million in gross proceeds through an initial public offering (IPO), according to an S-1 registration statement filed yesterday with the U.S. Securities and Exchange Commission.Menlo’s registration statement is among the last, if not the last, IPO filing of this year, in which no fewer than 18 of the Top 25 Biop